Most Read Articles
4 days ago
A direct switch to indacaterol/glycopyrronium (IND/GLY) from salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with up to one exacerbation in the previous year improves predose forced expiratory volume in 1 s (FEV1) and forced vital capacity without presenting new safety signals, a recent study has found.

Early abiraterone acetate treatment improves outcomes in CRPC patients

28 Feb 2018

In chemotherapy-naïve castrate-resistant prostate cancer (CRPC) patients, first- and second-line administration of abiraterone acetate (AA) treatment leads to favourable outcomes, a recent Japan study suggests.

Researchers retrospectively analysed the records of 69 CRPC patients who received AA treatment and classified them into two: the early group, who received AA as first- or second-line treatment (n=24), and the deferred group, who received AA as a third-line or later treatment (n=45).

In unadjusted analyses, only the timing of AA treatment was significantly associated with progression-free survival (PFS), such that those in the early group had better outcomes than those in the deferred group (hazard ratio [HR], 3.29; 95 percent CI, 1.66–6.51; p<0.001).

Adjusting for potential confounders did not attenuate the relationship. Although to a slightly lesser degree, early AA treatment remained significantly correlated with better PFS outcomes (HR, 2.99; 1.35–6.64; p<0.01).

Within the early group, there were no significant differences in outcomes between those who received AA as first- or second-line treatment. That is, patients treated first- or second-line treatment were statistically comparable in terms of prostate-specific antigen response, overall survival and PFS. All participants who received AA as second-line treatment were given flutamide as first-line therapy.

Five patients reported grade 3 adverse events, three of whom had hepatic function. Hypokalaemia and thrombocytopaenia were reported in one patient each. Other adverse events reported were either grade 1 or 2, the most common of which was an increase in alanine aminotransferase or aspartate aminotransferase levels.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
A direct switch to indacaterol/glycopyrronium (IND/GLY) from salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with up to one exacerbation in the previous year improves predose forced expiratory volume in 1 s (FEV1) and forced vital capacity without presenting new safety signals, a recent study has found.